Extended newborn screening using DNA methylation testing for fragile X syndrome in 17,107 infants.

Newborn screening by FMR1 methylation analysis (CGG expansion)

This study assesses the feasibility of population-scale newborn screening for fragile X syndrome (FXS). FMR1 methylation analysis by MS-QMA served as a first-tier test on newborn blood spots from 17,107 infants, with EpiTYPER and AmplideX CGG-sizing PCR for confirmation. A suggestive result was detected in 3 males and 36 females; second-tier testing confirmed FXS in two males and a full mutation in one female. Two females carried an FMR1 premutation (55 to 158 CGG repeats) that does not cause FXS. MS-QMA proved a feasible first-tier screen in both sexes.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

An interesting feasibility proof for newborn FXS screening, with a two-tier strategy limiting false positives. Detecting premutations raises result-return and counseling questions specific to this gene. Clinical value will hinge on the availability of early interventions and an adapted ethical framework.

Analysis by Dr Thibaut Benquey